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Age-related macular degeneration (AMD), a retinal degenerative disease, is the leading 
cause of central vision loss among the elderly population in developed countries and an 
increasing global burden. The major risk is aging, compounded by other environmental 
factors and association with genetic variants for risk of progression. Although the etiology 
of AMD is not yet clearly understood, several pathogenic pathways have been proposed, 
including dysfunction of the retinal pigment epithelium, inflammation, and oxidative 
stress. The identification of AMD susceptibility genes encoding complement factors and 
the presence of complement and other inflammatory mediators in drusen, the hallmark 
deposits of AMD, support the concept that local inflammation and immune-mediated 
processes play a key role in AMD pathogenesis that may be accelerated through sys-
temic immune activation. In this regard, increased levels of circulating C-reactive protein 
(CRP) have been associated with higher risk of AMD. Besides being a risk marker for 
AMD, CRP may also play a role in the progression of the disease as it has been identified 
in drusen, and we have recently found that its monomeric form (mCRP) induces blood 
retinal barrier disruption in vitro. In this review, we will address recent evidence that links 
CRP and AMD pathogenesis, which may open new therapeutic opportunities to prevent 
the progression of AMD.
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inTRODUCTiOn
Age-related macular degeneration (AMD) is the primary cause of irreversible vision loss among the 
aging population worldwide. The disease affects up to 1.75 million individuals alone in the United 
States, and this number could increase up to 3 million by 2020 (1–3). Worldwide, the projected 
number of people with AMD in 2020 is 196 million (95% CrI 140–261), which increases to 288 
million in 2040 (205–399) (4). AMD is a complex, degenerative, and progressive disease involving 
multiple genetic and environmental factors, which can ultimately result in severe visual loss. The 
disease-causing molecular mechanisms remain unknown, although inflammatory processes have 
been implicated by the identification of AMD susceptibility genes encoding complement factors 
(5, 6) and by the presence of complement proteins in drusen, the hallmark deposits associated with 
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AMD and other features of immune activation, including inflam-
masome activation (7–10).
The pathology of AMD is characterized by vision loss due to 
alterations in the macula, the central zone of the retina. Visual 
dysfunction in AMD is associated with the degeneration of 
the outer portion of the retina, the outer blood retinal barrier 
(oBRB), which includes the retinal pigment epithelium (RPE), 
the Bruch’s membrane, and the choriocapillaris. This is followed 
(or in some cases preceded) by degeneration of the light-sensing 
photoreceptor cells supported by the oBRB. Degeneration of the 
RPE seems to begin with impaired clearance of cellular waste. The 
initial clinical manifestations of AMD are characterized by the 
presence of drusen, deposits of extracellular matrix, and pigment 
that form most commonly within the macula at the choroid–RPE 
interface. Based on the size and number of drusen, the presence 
of atrophy, and/or neovascularization, AMD is classified into 
five stages of increasing severity (11). Early and intermediate 
AMD are characterized by the presence of small or large drusen 
and RPE irregularities. Forms of late AMD include geographic 
atrophy and neovascularization, both of which can lead to severe 
central visual impairment and legal blindness due to degenerative 
and neovascular alterations in the macula, respectively (11, 12). 
Although, currently, neovascular AMD can be controlled with 
antiangiogenic agents that block vascular endothelial growth 
factor, most treated patients still suffer from visual impairment 
as they develop fibrosis and atrophy, and more than one-third of 
them show long-term loss of effect (13). Most concerning is that 
there is still no approved treatment for geographic atrophy.
Age is the primary risk factor for AMD. Physiological changes 
that occur with aging may impair cellular function in those at 
risk of the disease (14). In addition, other genetic and environ-
mental risk factors are associated with AMD, most significantly 
smoking (15). A variety of complement pathway-associated gene 
variants, such as complement factor H (CFH) (16), factor B, and 
the complement components C2 and C3 have associations with 
AMD pathogenesis (17). Smoking increases the risk of the exuda-
tive type of AMD both in females and men (18, 19), and there is 
a direct association between AMD and raised concentration of 
cholesterol (20). In addition, small increases in the plasma levels 
of C-reactive protein (CRP) are an additional associated risk fac-
tor for AMD (21). Dietary interventions with carotenoids, oral 
supplementation with high levels of antioxidants and minerals, 
or high intake of omega-3 fatty acids and fish arguably slow the 
course of the disease and are implemented clinically to various 
degrees worldwide (22, 23). Light and photosensitization reac- 
tions may also play a role in the development of AMD via synthe-
sis of reactive oxygen species, with consequent damage to the RPE 
and Bruch’s membrane (24). Finally, chronic systemic disorders 
such as atherosclerosis (25), diabetes (26), and cardiovascular 
diseases (27) contribute to the risk for AMD development.
Although the etiology of AMD in terms of multifactorial risk 
factors are increasingly well documented, the patho-etiology 
of how oxidative stress, atherosclerotic-like changes, RPE cell 
dysfunction, genetic variants, and inflammation/altered tissue 
immune responses interlink is less well defined (28–30). One 
notion to enquire further is the influence of systemic immunity 
or alarming, acute phase responses in the progression of AMD, 
not dissimilar to dementia (31). In this context, elevated CRP 
levels are found both in the blood of AMD patients and in the 
eyes of carriers of a CFH polymorphism associated to the risk 
for developing the disease, providing a molecular clue to AMD 
pathogenesis and to how genetic risk factors may influence its 
course (21, 32). In this review, we summarize the main findings 
that support the implication of CRP in the pathogenesis of AMD 
and its connection with aging.
inFLAMMATiOn AnD AMD
Chronic inflammation is a prolonged condition in which tissue 
injury and attempts at repair coexist, leading to tissue remod-
eling and dysfunction. It is the common pathological basis for 
age-associated diseases such as cardiovascular disease, diabetes, 
cancer, Alzheimer’s disease, but also AMD. A multitude of bodily 
changes occur with aging that contribute to the initiation and 
development of inflammation. In particular, the immune system 
of elderly individuals is characterized by a basal systemic inflam-
matory state, as increased levels of proinflammatory cytokines 
and acute phase reactants are observed with aging (33). Local 
inflammation and immune-mediated processes play a central 
role in AMD pathogenesis (34–36).
A competent immune system in the eye is necessary to main-
tain intraocular health. The network of macrophages and micro-
glia along with the RPE and choroidal endothelial cells maintain 
tissue homeostasis allowing cellular debris removal and pathogen 
surveillance. Besides the presence of tissue-resident immune 
cells, inflammatory molecules are constitutively expressed in the 
subretinal space, meaning that there is a persistent inflammatory 
state, known as para-inflammation, which deals with danger 
signals and protects the tissue against over-inflammation and 
destruction. Proteomic and histochemical analysis of ocular 
drusen have shown that these deposits contain inflammatory 
proteins and complement components that mediate local inflam-
mation, such as C5, C9, CRP, amyloid A, fibrinogen, and vitronec-
tin (7, 37, 38). The complement system is one of the main effectors 
of the innate immune response. The activation of the complement 
system culminates in the formation of the membrane attack com-
plex and, potentially, cell lysis. Accumulation of membrane attack 
complex in the macula increases with aging and in AMD patients 
compared to age-matched controls (39–42). On the other hand, 
some diseases that are associated with complement activation 
have been independently linked to AMD (43), and a number of 
complement pathway-associated genes have been recognized as 
important driving factors of AMD pathogenesis. Some of these 
genetic variants might cause the complement system to be over-
active, resulting in a chronic inflammatory condition (42, 44). 
This abnormal inflammatory stimulus adversely affects RPE cells 
and promotes drusen formation (45). The strongest genetic risk 
factor for AMD known to date is a common polymorphism in 
the CFH gene (c.1277T > C, p.Tyr402His); the CFH p.Tyr402His 
variant (in following termed CFHH402) increases the risk for AMD 
approximately twofold to fourfold for heterozygous and fivefold 
to sevenfold for homozygous individuals (5, 16, 46).
FH is a major inhibitor of the alternate complement pathway 
that regulates complement activation in plasma, host cells, and 
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tissue, in particular, at sites of tissue inflammation, following 
injury or during degeneration (47). The protein is essentially 
comprised of 20 tandem Sushi domains, also known as short 
consensus repeat (SCR) or complement control protein modules. 
The exchanged residue in the FHH402 variant is located in domain 
SCR7, which mediates the binding to CRP, malondialdehyde 
(MDA), and to cell surfaces through interactions with heparan 
sulfate (HS) chains (48, 49). The “at risk” variant of FH shows an 
impaired binding to these ligands, which could result in increased 
complement activation and chronic local inflammation. MDA 
is a toxic by-product of lipid peroxidation and Weismann et al. 
showed that FH binds MDA through SCR7 and protects from 
oxidative stress. Notably, the “at risk” variant resulted in severely 
reduced factor-I-mediated C3 cleavage when bound to MDA 
(50). Regarding HS, the “non-risk” variant of FH can bind to 
multiple sites on HS chains in BM due to its wide specificity. 
Instead, the 402H variant only binds to highly sulphated motifs 
within HS (51, 52). Thus, if insufficient FH is present in BM, as is 
the case for the 402H variant, there will be increased activation 
of the complement cascade and the release of pro-inflammatory 
mediators. However, increased inflammation could be also due to 
the impaired binding of CRP to the FH from the “at risk” variant.
STRUCTURe AnD FUnCTiOn OF CRP
CRP is the prototypical acute-phase reactant and an active regu-
lator of the innate immune system; CRP levels increase rapidly 
in response to infection, inflammation, and tissue injury (53). 
It is a highly conserved protein of the pentraxin family, mainly 
produced in the liver. Among the multiple functions ascribed 
to CRP are activation of the classical complement pathway and 
inactivation of the alternative pathway (53). In plasma, CRP 
exists as a cyclic, noncovalent pentamer of 125 kDa composed 
of five identical subunits (pCRP), and which is stabilized 
by numerous electrostatic and Van-der-Waals interactions 
(54, 55). Native pCRP binds in a Ca2+-dependent manner to 
phosphocholine (PCh)-containing ligands such as pneumococ-
cal cell wall C-polysaccharide, but also to the surface of necrotic 
cells and parasites (55–58). Oxidative stress, low pH, and bioac-
tive lipids from activated or damaged cells can dissociate the 
CRP pentamer into its 23-kDa subunits (59–62). This poorly 
soluble, tissue-based monomeric form (mCRP) possesses distinct 
biological functions compared to pCRP (60, 63–67). The disso-
ciation mechanism of CRP requires, first, a reversible structural 
transition within pCRP subunits, but without disrupting the 
pentameric symmetry (60, 68, 69). This rapid conversion to the 
modified form (pCRP*) may contribute to acute phase amplifica-
tion of the inflammatory response. Then, the pCRP* → mCRP 
irreversible transition is likely to occur at sites of persistent chronic 
inflammation, where the inflammatory microenvironment— 
characterized by acidic conditions, oxidative stress, and presence 
of bioactive phospholipids—continuously favors dissociation of 
the pentameric arrangement. mCRP would then effectively trig-
ger proinflammatory responses and regulate complement (68). 
Indeed, the dissociation of circulating pCRP to mCRP in areas of 
inflammation has been observed in vivo in a rat model of acute 
inflammation. Mechanistically, this process is dependent on 
exposure of lysophosphatidylcholine (LysoPCh), a bioactive lipid 
that is generated after phospholipase A2 activation on activated 
cell membranes (62, 70).
The crystal structure of native pCRP in complex with PCh 
shows how large PCh-containing ligands may be specifically 
bound by CRP and offers clues to the mechanism of mCRP for-
mation (54). The PCh ligand-binding site is located in a groove 
of a β-sheet on the so-called “B face” of the pentamer (Figure 1). 
Multipoint attachment of this planar face of the CRP molecule 
to a PCh-bearing surface would leave available, on the opposite 
A face, the recognition sites for complement C1q. In the absence 
of Ca2+, residues 140–150 form a loop that projects away from 
the body of each CRP subunit exposing a normally hidden 
proteolysis site. Cleavage at this site facilitates that individual 
CRP subunits move apart, thus exposing a neoepitope (residues 
199–206, colored yellow in Figure 1C) that is recognized by anti-
mCRP-specific antibodies (9C9 or 3H12) (68, 71). The globular 
head of C1q is then able to insert itself into the inner annular 
void of pCRP* (the relaxed conformation) forcing the subunits 
further apart (noteworthy, C1q is unable to bind to the “strained” 
pCRP conformation) (68). Finally, the CRP subunits might dis-
sociate, likely accompanied by partial unfolding to generate the 
mCRP form (72, 73). This process would enable CRP to target 
physiologically and/or pathologically significant complement 
activation.
MOLeCULAR CHAnGeS in THe OBRB  
in AMD: inTeRACTiOn BeTween  
CRP AnD FH
The fact that patients with AMD and individuals with the CFHH402 
variant show increased systemic and local levels of CRP, respec-
tively, provides a molecular hint on the pathogenesis of AMD. 
AMD lesion formation has been proposed to share mechanisms 
with atherosclerotic plaque formation, which is initiated with 
low-density lipoprotein retention within the arterial wall (74). 
Although a thorough discussion of the cross-connections 
between CRP and cardiovascular diseases is beyond the scope of 
this review, it is noteworthy that patients with clinical evidence of 
atherosclerosis (stroke, coronary, and peripheral artery disease) 
show modestly but significantly increased CRP levels (25, 75, 76).
Seddon and coworkers were the first to address the relationship 
between elevated CRP concentrations and AMD progression. 
They found a significant increase in circulating CRP levels as the 
disease progressed, and showed that low-, medium-, and high-
risk AMD groups are associated with serum CRP concentrations 
below 0.5, between 0.5 and 10.0, and over 10.0 mg/L, respectively 
(21, 77, 78). However, this association has not been universally 
confirmed (79). A more recent study by the Seddon group shows 
that high levels of circulating CRP are associated with a higher 
risk of AMD, regardless of the CFH genotype (80).
Other authors have recently attempted to triangulate the asso-
ciation between plasma concentrations of CRP, four CRP genetic 
variants reported to influence CRP circulating levels, and the risk 
of advanced AMD (81). They found that two of the genetic vari-
ants do share some association with plasma CRP concentrations. 
FiGURe 1 | Proposed model of the conversion from the strained to the relaxed conformations of pentameric C-reactive protein (CRP). (A) Solid surface 
representation of the crystal structure of human CRP in its “strained” conformation (pCRP) bound to phosphocholine (PCh) (PDB entry 1B09) (54). The view  
shown is from the membrane binding “B face” of pCRP. The individual subunits are represented color-coded, with PCh (cream spheres) and Ca2+ ions (black 
spheres) occupying the ligand binding site on each subunit. (B) Modeled interaction of pCRP with a phospholipid bilayer. View is from “above,” looking down onto 
the pCRP “A face.” Each pCRP subunit can independently bind to a PCh head group of the bilayer. Exposure to lysoPCh triggers reversible conversion of pCRP  
to pCRP*. (C) Pentameric pCRP*, same view as in (B). As the individual CRP subunits move apart, a neoepitope (colored yellow) is exposed. (D) The globular  
head of C1q inserts itself into the inner annular void of pCRP* forcing the subunits further apart [adapted from Braig et al. (68)].
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However, none of the four variants was significantly associated 
with the risk of AMD. Their findings have important implica-
tions for our understanding of the pathophysiology of AMD, 
in particular, for the distinct roles played by local and systemic 
inflammation in this regard. However, it must be considered that 
other factors such as C3 genotype and smoking strongly affect 
circulating CRP levels. Thus, these results do not preclude a direct 
link between AMD pathophysiology through complement activa-
tion and chronic inflammation, and plasma CRP concentrations 
might still be useful as an AMD biomarker. Important differences 
exist between systemic inflammation and the local inflammatory 
macular tissue microenvironment.
Since CFH risk haplotypes are associated with increased com-
plement activation in human macular tissue (82) but not in the 
circulation (83, 84), it is important to determine the localization 
and abundance of both CRP and FH in the extra-macular choroid 
of individuals homozygous for the high-risk CFHH402 genotype, as 
compared to those homozygous for the low-risk CFHY402 variant. 
This investigation, reported by Johnson and colleagues, showed 
that the localization and abundance of FH do not differ between 
CFH genotypes (32). However, choroidal immuno-staining of 
CRP was significantly higher in the CFHH402 eyes compared to 
the CFHY402 eyes. Interestingly, these differences between the 
CFH homozygotes were independent of AMD status. Because the 
high-risk allele affects binding of FH to CRP (85), deficient FH 
binding could potentially increase the pro-inflammatory activity 
of CRP in choroidal tissue, contributing to AMD pathogenesis. 
Also along these lines, Bhutto and colleagues have reported 
distinct patterns of localization for FH and CRP in the aging 
eye. Most notably, these authors found an inverse relationship 
between CRP and FH levels in macular tissue from patients with 
advanced AMD as compared to age-matched control individuals 
(86). In AMD patients, Bruch’s membrane, drusen, and choroidal 
vessel walls all showed increased labeling of CRP and decreased 
labeling of FH compared to controls. These findings support the 
idea that the macula of AMD patients has an increased inflamma-
tory microenvironment with decreased capacity for complement 
inhibition.
Although FH is known to bind CRP, there was certain contro-
versy regarding the relevance of the monomeric and pentameric 
forms in this regard. For instance, two separate binding sites for 
pCRP were located on domains SCR4-6 and SCR16-20, respec-
tively (49). On the other hand, FH showed strong binding to 
denatured, monomeric CRP, rather than to the native multimeric 
form (87, 88). We have recently shown that mCRP, but not the 
pentameric form, contributes to oBRB disruption in vitro (89). 
The functional integrity of the RPE, critical for the maintenance 
of the specialized environment of the neural retina, is dependent 
FiGURe 2 | A unified mechanism of mCRP-induced proinflammatory responses and the role of the CFH p.Tyr402His polymorphism in age-related macular 
degeneration (AMD). Generation of mCRP is accelerated in vivo under inflammatory conditions by bioactive lipids such as lysophosphatidylcholine (lysoPC)  
exposed on the surface of microparticles, activated or damaged cells. mCRP is recognized on the cell surface, leading to activation of MAPK pathways and 
ultimately enhances expression of proinflammatory cytokines and disrupts the outer blood retinal barrier. Binding of FH to mCRP attenuates this inflammatory 
response, but the FHH402 variant is less effective in this regard, both because of its altered binding to glycosaminoglycans (52), but, in particular, due to its markedly 
lower affinity for mCRP. The unchecked inflammatory response leads eventually to progression of AMD and vision loss [figure adapted from Molins et al. (90)].
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on the structures of tight junctions. Exposure to mCRP, but 
not pCRP, significantly increased the paracellular permeability 
of the RPE compared with that of untreated cells, suggesting 
that mCRP could compromise the barrier function of the RPE 
monolayer. Notably, mCRP was also able to disturb the expres-
sion and distribution of the TJ proteins, ZO-1, and occludin. In 
another study, we also showed that mCRP confers a proinflam-
matory phenotype to RPE cells as it increases production of 
the proinflammatory cytokines IL-8 and CCL2 (Figure 2) (90). 
The mCRP-induced pro-inflammatory phenotype was further 
demonstrated by the significantly increased rates of peripheral 
blood mononuclear cells migration treated with conditioned 
medium from RPE cells after being exposed to mCRP, but not 
with conditioned media from either untreated cells or from cells 
exposed to pCRP. The oBRB disruption induced by mCRP could 
conceivably permit passage of inflammatory cells into the retina, 
further contributing to chronic inflammation and accelerating 
tissue damage.
Moreover, we also showed that the “non-risk” FH variant 
(CFHY402) can effectively bind to mCRP to dampen mCRP pro-
inflammatory activity. Notably, FH from AMD patients carrying 
the risk polymorphism for AMD shows an impaired binding 
to mCRP and, therefore, its proinflammatory effects remain 
unrestrained (Figure 2) (90). In line with and highlighting our 
findings, Chirco et al. have recently shown that mCRP is the more 
abundant form of CRP in human RPE-choroid, and that mCRP 
levels are elevated in individuals with the high-risk CFH geno - 
type (91), which could thus sustain chronic inflammation 
contributing to the progression of AMD in CFHH402 individuals. 
Moreover, pro-inflammatory mCRP significantly affects endothe-
lial cell phenotypes, suggesting a role for mCRP in choroidal 
vascular dysfunction in AMD as well.
It is also interesting to note that, in our cohort of AMD patients, 
those carrying the risk variant of CFH had significantly higher 
levels of systemic IL-8 and CRP than healthy subjects carrying 
the non-risk allele (90). Further, the levels of these proteins were 
positively correlated in AMD patients homozygous for the risk 
CFHH402 variant. These results are in conflict with previous stud-
ies showing that CRP levels and the CFHH402 polymorphism were 
independent risk factors for AMD (80). We observed differences 
in circulating CRP concentrations between subjects carrying the 
different CFH variants, albeit in a smaller population. Our results 
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might explain the previously reported higher risk of AMD within 
genetically susceptible individuals when CRP concentrations are 
high (80). We hypothesize that higher levels of circulating CRP 
could derive in higher mCRP concentrations in microenviron-
ments that favor dissociation, such as inflammatory or apoptotic 
conditions, which in the case of patients carrying the CFHH402 risk 
variant would further cause unchecked inflammation. However, 
it is unclear where, when, and how mCRP dissociates within 
the oBRB. mCRP could either dissociate distantly in activated 
endothelium or locally within the RPE. Unchecked mCRP 
activity may sustain chronic inflammation thus favoring AMD 
progression. Whether this provokes disease or not requires vali-
dation, but this process alone may not be sufficient to explain all 
the immune-related changes we observe in AMD and, therefore, 
further research is warranted.
TARGeTinG MOnOMeRiC CRP in AMD
The recent findings from us and others discussed above reinforce 
the importance of mCRP in chronic inflammation and point to 
the pCRP dissociation process and/or mCRP itself as novel thera-
peutic targets for AMD. Indeed, therapies associated with a reduc-
tion in systemic CRP levels are successfully used in other chronic 
inflammatory diseases such as atherosclerosis, where CRP is an 
important player (76). However, given that CRP may have a more 
important role in the macular tissue, it might be more appropriate 
to target local CRP for AMD treatment. Blocking the dissociation 
of pCRP with 1,6-bis-PCh, a compound that stabilizes CRP in a 
decameric form, abolished the proinflammatory effects of mCRP 
in  vivo (62). Restrictively, 1,6-bis PCh is not suitable for clini-
cal purposes due to its pharmacokinetics and its low affinity for 
pCRP (150 nM) (62). Thus, a more potent drug with higher oral 
bioavailability, higher affinity for pCRP, and prolonged half-time 
needs to be designed to efficiently target the pCRP dissociation 
process as an innovative therapeutic strategy. Blocking LysoPCh 
formation with PLA2 inhibitors may be another interesting 
approach to inhibit pCRP dissociation. Alternatively, therapeutic 
approaches aimed to enhance FH-mCRP binding could be devel-
oped to block mCRP proinflammatory activities, thus preventing 
the progression of AMD.
COnCLUSiOn
The reduced ability to control the balance between pro- and 
anti-inflammatory signals associated with aging might promote 
a switch to chronic inflammation in the macular tissue. This 
scenario could then favor CRP dissociation and mCRP accumu-
lation further fueling chronic inflammation and tissue damage, 
especially in those patients with the “risk” FH variant, CFHH402, 
where FH is unable to dampen mCRP proinflammatory activity 
and to localize to HS in Bruch’s membrane. A combination of 
poor binding of the FH H402 variant to Bruch’s membrane and 
mCRP, combined with aging associated processes such HS loss 
and an increased proinflammatory environment, may eventu-
ally result in complement activation, persistent mCRP-induced 
inflammation, and thereby contribute to AMD progression. 
Future research is warranted to confirm the contribution of 
mCRP to disease etiology and progression, and eventually to test 
the therapeutic potential of compounds that either prevent CRP 
dissociation or stimulate FH binding to mCRP.
AUTHOR COnTRiBUTiOnS
BM, PF-P, SR-V, AA, and AD contributed to the design of the 
project and manuscript preparation, and all authors reviewed the 
manuscript.
FUnDinG
This work was supported by the Ministry of Science and 
Innovation of Spain, “Instituto de Salud Carlos III,” “Fondo de 
Investigación Sanitaria” (RD16/0008).
ReFeRenCeS
1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related 
macular degeneration. Am J Ophthalmol (2004) 137(3):486–95. doi:10.1016/
S0002-9394(04)00052-2 
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. 
Epidemiology of age-related maculopathy: a review. Eur J Epidemiol (2003) 
18(9):845–54. doi:10.1023/A:1025643303914 
3. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence 
of age-related macular degeneration in the US population. Arch Ophthalmol 
(2011) 129(1):75–80. doi:10.1001/archophthalmol.2010.318 
4. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global preva-
lence of age-related macular degeneration and disease burden projection for 
2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 
(2014) 2(2):e106–16. doi:10.1016/S2214-109X(13)70145-1 
5. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. 
Complement factor H polymorphism and age-related macular degeneration. 
Science (2005) 308(5720):421–4. doi:10.1126/science.1110189 
6. Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, 
et al. A large genome-wide association study of age-related macular degener-
ation highlights contributions of rare and common variants. Nat Genet (2016) 
48(2):134–43. doi:10.1038/ng.3448 
7. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with 
aging and age-related macular degeneration contain proteins common to 
extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, 
and dense deposit disease. FASEB J (2000) 14(7):835–46. doi:10.1096/
fasebj.14.7.835 
8. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular 
degeneration. Nat Rev Immunol (2013) 13(6):438–51. doi:10.1038/nri3459 
9. Lambert NG, ElShelmani H, Singh MK, Mansergh FC, Wride MA, Padilla M, 
et al. Risk factors and biomarkers of age-related macular degeneration. Prog 
Retin Eye Res (2016) 54:64–102. doi:10.1016/j.preteyeres.2016.04.003 
10. Whitcup SM, Sodhi A, Atkinson JP, Holers VM, Sinha D, Rohrer B, et al. The 
role of the immune response in age-related macular degeneration. Int J Inflam 
(2013) 2013:348092. doi:10.1155/2013/348092 
11. Ferris FL III, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. 
Clinical classification of age-related macular degeneration. Ophthalmology 
(2013) 120(4):844–51. doi:10.1016/j.ophtha.2012.10.036 
12. Age-Related Eye Disease Study Research Group. The age-related eye disease 
study system for classifying age-related macular degeneration from stereoscopic 
color fundus photographs: the age-related eye disease study report number 6. 
Am J Ophthalmol (2001) 132(5):668–81. doi:10.1016/S0002-9394(01)01218-1 
13. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year 
outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and 
7Molins et al. CRP as a Therapeutic Target in AMD
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 808
HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 
(2013) 120(11):2292–9. doi:10.1016/j.ophtha.2013.03.046 
14. Demontis F, Piccirillo R, Goldberg AL, Perrimon N. Mechanisms of skeletal 
muscle aging: insights from Drosophila and mammalian models. Dis Model 
Mech (2013) 6(6):1339–52. doi:10.1242/dmm.012559 
15. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, et  al. 
Smoking and age related macular degeneration: the number of pack years of 
cigarette smoking is a major determinant of risk for both geographic atrophy 
and choroidal neovascularisation. Br J Ophthalmol (2006) 90(1):75–80. 
doi:10.1136/bjo.2005.073643 
16. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement 
factor H polymorphism in age-related macular degeneration. Science (2005) 
308(5720):385–9. doi:10.1126/science.1109557 
17. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et  al. 
Complement C3 variant and the risk of age-related macular degeneration. 
N Engl J Med (2007) 357(6):553–61. doi:10.1056/NEJMoa072618 
18. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study 
of cigarette smoking and risk of age-related macular degeneration in men. 
JAMA (1996) 276(14):1147–51. doi:10.1001/jama.1996.03540140035023 
19. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of 
cigarette smoking and age-related macular degeneration in women. JAMA 
(1996) 276(14):1141–6. doi:10.1001/jama.1996.03540140029022 
20. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR, et al. 
Risk factors for incident age-related macular degeneration: pooled findings 
from 3 continents. Ophthalmology (2004) 111(7):1280–7. doi:10.1016/j.ophtha. 
2003.11.010 
21. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between 
C-reactive protein and age-related macular degeneration. JAMA (2004) 
291(6):704–10. doi:10.1001/jama.291.6.704 
22. Age-Related Eye Disease Study Research Group. A randomized, placebo- 
controlled, clinical trial of high-dose supplementation with vitamins C and E 
and beta carotene for age-related cataract and vision loss: AREDS report no. 9. 
Arch Ophthalmol (2001) 119(10):1439–52. doi:10.1001/archopht.119.10.1439 
23. SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris FL III, Gensler GR, 
et al. The relationship of dietary lipid intake and age-related macular degener-
ation in a case-control study: AREDS report no. 20. Arch Ophthalmol (2007) 
125(5):671–9. doi:10.1001/archopht.125.5.671 
24. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and 
age-related macular degeneration. Mol Vis (1999) 5:32. 
25. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of 
cardiovascular disease as risk factors for age-related macular degeneration. 
Ophthalmology (2005) 112(12):2076–80. doi:10.1016/j.ophtha.2005.07.004 
26. Choi JK, Lym YL, Moon JW, Shin HJ, Cho B. Diabetes mellitus and early 
age-related macular degeneration. Arch Ophthalmol (2011) 129(2):196–9. 
doi:10.1001/archophthalmol.2010.355 
27. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and 
the long-term incidence of age-related macular degeneration: the Blue 
Mountains Eye Study. Ophthalmology (2007) 114(6):1143–50. doi:10.1016/j.
ophtha.2006.09.033 
28. Miller JW. Age-related macular degeneration revisited – piecing the puzzle: 
the LXIX Edward Jackson memorial lecture. Am J Ophthalmol (2013) 
155(1):1–35.e13. doi:10.1016/j.ajo.2012.10.018 
29. Nussenblatt RB, Lee RW, Chew E, Wei L, Liu B, Sen HN, et  al. Immune 
responses in age-related macular degeneration and a possible long-term 
therapeutic strategy for prevention. Am J Ophthalmol (2014) 158(1):5–11.e2. 
doi:10.1016/j.ajo.2014.03.014 
30. Zarbin MA. Current concepts in the pathogenesis of age-related macular 
degeneration. Arch Ophthalmol (2004) 122(4):598–614. doi:10.1001/archopht. 
122.4.598 
31. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic 
inflammation and disease progression in Alzheimer disease. Neurology (2009) 
73(10):768–74. doi:10.1212/WNL.0b013e3181b6bb95 
32. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. 
Individuals homozygous for the age-related macular degeneration risk- 
conferring variant of complement factor H have elevated levels of CRP in 
the choroid. Proc Natl Acad Sci U S A (2006) 103(46):17456–61. doi:10.1073/
pnas.0606234103 
33. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of 
innate immunity. Nat Rev Immunol (2013) 13(12):875–87. doi:10.1038/nri3547 
34. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflam- 
mation in the pathogenesis of age-related macular degeneration. Surv 
Ophthalmol (2006) 51(2):137–52. doi:10.1016/j.survophthal.2005.12.001 
35. Dick AD. Doyne lecture 2016: intraocular health and the many faces of inflam-
mation. Eye (Lond) (2017) 31(1):87–96. doi:10.1038/eye.2016.177 
36. Kim Y, Tarallo V, Kerur N, Yasuma T, Gelfand BD, Bastos-Carvalho A, 
et  al. DICER1/Alu RNA dysmetabolism induces caspase-8-mediated cell 
death in age-related macular degeneration. Proc Natl Acad Sci U S A (2014) 
111(45):16082–7. doi:10.1073/pnas.1403814111 
37. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflam-
mation in the formation of drusen in the aging eye. Am J Ophthalmol (2002) 
134(3):411–31. doi:10.1016/S0002-9394(02)01624-0 
38. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, et  al. 
Drusen proteome analysis: an approach to the etiology of age-related macular 
degeneration. Proc Natl Acad Sci U S A (2002) 99(23):14682–7. doi:10.1073/
pnas.222551899 
39. Mullins RF, Schoo DP, Sohn EH, Flamme-Wiese MJ, Workamelahu G, 
Johnston RM, et al. The membrane attack complex in aging human chorio-
capillaris: relationship to macular degeneration and choroidal thinning. Am 
J Pathol (2014) 184(11):3142–53. doi:10.1016/j.ajpath.2014.07.017 
40. Seth A, Cui J, To E, Kwee M, Matsubara J. Complement-associated deposits in 
the human retina. Invest Ophthalmol Vis Sci (2008) 49(2):743–50. doi:10.1167/
iovs.07-1072 
41. Skeie JM, Fingert JH, Russell SR, Stone EM, Mullins RF. Complement 
component C5a activates ICAM-1 expression on human choroidal endothelial 
cells. Invest Ophthalmol Vis Sci (2010) 51(10):5336–42. doi:10.1167/iovs. 
10-5322 
42. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, 
et al. A common haplotype in the complement regulatory gene factor H (HF1/
CFH) predisposes individuals to age-related macular degeneration. Proc Natl 
Acad Sci U S A (2005) 102(20):7227–32. doi:10.1073/pnas.0501536102 
43. Nitsch D, Douglas I, Smeeth L, Fletcher A. Age-related macular degen-
eration and complement activation-related diseases: a population-based 
case-control study. Ophthalmology (2008) 115(11):1904–10. doi:10.1016/j.
ophtha.2008.06.035 
44. Kawa MP, Machalinska A, Roginska D, Machalinski B. Complement system 
in pathogenesis of AMD: dual player in degeneration and protection of retinal 
tissue. J Immunol Res (2014) 2014:483960. doi:10.1155/2014/483960 
45. Jakobsdottir J, Conley YP, Weeks DE, Ferrell RE, Gorin MB. C2 and CFB genes 
in age-related maculopathy and joint action with CFH and LOC387715 genes. 
PLoS One (2008) 3(5):e2199. doi:10.1371/journal.pone.0002199 
46. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et  al. 
Complement factor H variant increases the risk of age-related macular 
degeneration. Science (2005) 308(5720):419–21. doi:10.1126/science.1110359 
47. Langford-Smith A, Keenan TD, Clark SJ, Bishop PN, Day AJ. The role of com-
plement in age-related macular degeneration: heparan sulphate, a ZIP code 
for complement factor H? J Innate Immun (2014) 6(4):407–16. doi:10.1159/ 
000356513 
48. Giannakis E, Jokiranta TS, Male DA, Ranganathan S, Ormsby RJ, Fischetti VA, 
et al. A common site within factor H SCR 7 responsible for binding hepa-
rin, C-reactive protein and streptococcal M protein. Eur J Immunol (2003) 
33(4):962–9. doi:10.1002/eji.200323541 
49. Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds 
at two independent sites to C-reactive protein in acute phase concentrations. 
J Biol Chem (2010) 285(2):1053–65. doi:10.1074/jbc.M109.044529 
50. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P, 
et al. Complement factor H binds malondialdehyde epitopes and protects from 
oxidative stress. Nature (2011) 478(7367):76–81. doi:10.1038/nature10449 
51. Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. 
Identification of factor H-like protein 1 as the predominant complement 
regulator in Bruch’s membrane: implications for age-related macular 
degeneration. J Immunol (2014) 193(10):4962–70. doi:10.4049/jimmunol. 
1401613 
52. Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, et  al. 
Impaired binding of the age-related macular degeneration-associated com-
plement factor H 402H allotype to Bruch’s membrane in human retina. J Biol 
Chem (2010) 285(39):30192–202. doi:10.1074/jbc.M110.103986 
53. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem (2004) 
279(47):48487–90. doi:10.1074/jbc.R400025200 
8Molins et al. CRP as a Therapeutic Target in AMD
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 808
54. Thompson D, Pepys MB, Wood SP. The physiological structure of human 
C-reactive protein and its complex with phosphocholine. Structure (1999) 
7(2):169–77. doi:10.1016/S0969-2126(99)80023-9 
55. Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phos-
phate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 
(1971) 136(2):612–4. doi:10.3181/00379727-136-35323 
56. Volanakis JE, Wirtz KW. Interaction of C-reactive protein with artificial 
phosphatidylcholine bilayers. Nature (1979) 281(5727):155–7. doi:10.1038/ 
281155a0 
57. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds 
to both oxidized LDL and apoptotic cells through recognition of a common 
ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 
(2002) 99(20):13043–8. doi:10.1073/pnas.192399699 
58. Ahmed UK, Maller NC, Iqbal AJ, Al-Riyami L, Harnett W, Raynes JG. The 
carbohydrate-linked phosphorylcholine of the parasitic nematode product 
ES-62 modulates complement activation. J Biol Chem (2016) 291(22): 
11939–53. doi:10.1074/jbc.M115.702746 
59. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, 
et al. Dissociation of pentameric to monomeric C-reactive protein on activated 
platelets localizes inflammation to atherosclerotic plaques. Circ Res (2009) 
105(2):128–37. doi:10.1161/CIRCRESAHA.108.190611 
60. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, et  al. Cell membranes 
and liposomes dissociate C-reactive protein (CRP) to form a new, biologically 
active structural intermediate: mCRP(m). FASEB J (2007) 21(1):284–94. 
doi:10.1096/fj.06-6722com 
61. Lauer N, Mihlan M, Hartmann A, Schlötzer-Schrehardt U, Keilhauer C, Scholl HP, 
et  al. Complement regulation at necrotic cell lesions is impaired by the 
age-related macular degeneration-associated factor-H His402 risk variant. 
J Immunol (2011) 187(8):4374–83. doi:10.4049/jimmunol.1002488 
62. Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, et al. 
Dissociation of pentameric to monomeric C-reactive protein localizes and 
aggravates inflammation: in  vivo proof of a powerful proinflammatory 
mechanism and a new anti-inflammatory strategy. Circulation (2014) 130(1): 
35–50. doi:10.1161/CIRCULATIONAHA.113.007124 
63. Khreiss T, József L, Hossain S, Chan JS, Potempa LA, Filep JG. Loss of pen-
tameric symmetry of C-reactive protein is associated with delayed apoptosis 
of human neutrophils. J Biol Chem (2002) 277(43):40775–81. doi:10.1074/jbc.
M205378200 
64. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement 
in C-reactive protein is required for proinflammatory actions on human 
endothelial cells. Circulation (2004) 109(16):2016–22. doi:10.1161/01.
CIR.0000125527.41598.68 
65. Khreiss T, Jozsef L, Potempa LA, Filep JG. Loss of pentameric symmetry 
in C-reactive protein induces interleukin-8 secretion through peroxynitrite 
signaling in human neutrophils. Circ Res (2005) 97(7):690–7. doi:10.1161/01.
RES.0000183881.11739.CB 
66. Molins B, Pena E, de la Torre R, Badimon L. Monomeric CRP is prothrombotic 
and dissociates from circulating pentameric CRP on adhered activated plate-
lets under flow. Cardiovasc Res (2011). doi:10.1093/cvr/cvr226 
67. Molins B, Peña E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive 
protein isoforms differ in their effects on thrombus growth. Arterioscler 
Thromb Vasc Biol (2008) 28(12):2239–46. doi:10.1161/ATVBAHA.108.174359 
68. Braig D, Nero TL, Koch HG, Kaiser B, Wang X, Thiele JR, et  al. Transi- 
tional changes in the CRP structure lead to the exposure of proinflammatory 
binding sites. Nat Commun (2017) 8:14188. doi:10.1038/ncomms14188 
69. Singh SK, Thirumalai A, Pathak A, Ngwa DN, Agrawal A. Functional trans-
formation of C-reactive protein by hydrogen peroxide. J Biol Chem (2017) 
292(8):3129–36. doi:10.1074/jbc.M116.773176 
70. Habersberger J, Strang F, Scheichl A, Htun N, Bassler N, Merivirta RM, et al. 
Circulating microparticles generate and transport monomeric C-reactive 
protein in patients with myocardial infarction. Cardiovasc Res (2012) 
96(1):64–72. doi:10.1093/cvr/cvs237 
71. Potempa LA, Yao ZY, Ji SR, Filep JG, Wu Y. Solubilization and purification 
of recombinant modified C-reactive protein from inclusion bodies using 
reversible anhydride modification. Biophys Rep (2015) 1:18–33. doi:10.1007/
s41048-015-0003-2 
72. Christopeit T, Gossas T, Danielson UH. Characterization of Ca2+ and phospho-
choline interactions with C-reactive protein using a surface plasmon resonance 
biosensor. Anal Biochem (2009) 391(1):39–44. doi:10.1016/j.ab.2009.04.037 
73. Mikolajek H, Kolstoe SE, Pye VE, Mangione P, Pepys MB, Wood SP. Structural 
basis of ligand specificity in the human pentraxins, C-reactive protein and 
serum amyloid P component. J Mol Recognit (2011) 24(2):371–7. doi:10.1002/
jmr.1090 
74. Curcio CA, Johnson M, Huang JD, Rudolf M. Aging, age-related macular 
degeneration, and the response-to-retention of apolipoprotein B-containing 
lipoproteins. Prog Retin Eye Res (2009) 28(6):393–422. doi:10.1016/j.
preteyeres.2009.08.001 
75. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive 
protein and low-density lipoprotein cholesterol levels in the prediction of first 
cardiovascular events. N Engl J Med (2002) 347(20):1557–65. doi:10.1056/
NEJMoa021993 
76. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, 
et al. Rosuvastatin to prevent vascular events in men and women with elevated 
C-reactive protein. N Engl J Med (2008) 359(21):2195–207. doi:10.1056/
NEJMoa0807646 
77. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of 
age-related macular degeneration: relative roles of genetic and environ-
mental influences. Arch Ophthalmol (2005) 123(3):321–7. doi:10.1001/
archopht.123.3.321 
78. Seddon JM, Gensler G, Klein ML, Milton RC. C-reactive protein and 
homocysteine are associated with dietary and behavioral risk factors for age- 
related macular degeneration. Nutrition (2006) 22(4):441–3. doi:10.1016/j.
nut.2005.12.004 
79. McGwin G, Hall TA, Xie A, Owsley C. The relation between C reactive protein 
and age related macular degeneration in the Cardiovascular Health Study. 
Br J Ophthalmol (2005) 89(9):1166–70. doi:10.1136/bjo.2005.067397 
80. Seddon JM, Gensler G, Rosner B. C-reactive protein and CFH, ARMS2/HTRA1 
gene variants are independently associated with risk of macular degeneration. 
Ophthalmology (2010) 117(8):1560–6. doi:10.1016/j.ophtha.2009.11.020 
81. Cipriani V, Hogg RE, Sofat R, Moore AT, Webster AR, Yates JRW, et  al. 
Association of C-reactive protein genetic polymorphisms with late age-related 
macular degeneration. JAMA Ophthalmol (2017) 135(9):909–16. doi:10.1001/
jamaophthalmol.2017.2191 
82. Keenan TD, Toso M, Pappas C, Nichols L, Bishop PN, Hageman GS. Assessment 
of proteins associated with complement activation and inflammation in 
maculae of human donors homozygous risk at chromosome 1 CFH-to-F13B. 
Invest Ophthalmol Vis Sci (2015) 56(8):4870–9. doi:10.1167/iovs.15-17009 
83. Ristau T, Paun C, Ersoy L, Hahn M, Lechanteur Y, Hoyng C, et al. Impact of 
the common genetic associations of age-related macular degeneration upon 
systemic complement component C3d levels. PLoS One (2014) 9(3):e93459. 
doi:10.1371/journal.pone.0093459 
84. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL, 
et al. Genetic control of the alternative pathway of complement in humans 
and age-related macular degeneration. Hum Mol Genet (2010) 19(1):209–15. 
doi:10.1093/hmg/ddp472 
85. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, Lindeman N, 
et al. Y402H polymorphism of complement factor H affects binding affinity 
to C-reactive protein. J Immunol (2007) 178(6):3831–6. doi:10.4049/jimmunol. 
178.6.3831 
86. Bhutto IA, Baba T, Merges C, Juriasinghani V, McLeod DS, Lutty GA. 
C-reactive protein and complement factor H in aged human eyes and eyes 
with age-related macular degeneration. Br J Ophthalmol (2011) 95(9):1323–30. 
doi:10.1136/bjo.2010.199216 
87. Bíró A, Rovó Z, Papp D, Cervenak L, Varga L, Füst G, et al. Studies on the inter-
actions between C-reactive protein and complement proteins. Immunology 
(2007) 121(1):40–50. doi:10.1111/j.1365-2567.2007.02535.x 
88. Hakobyan S, Harris CL, van den Berg CW, Fernandez-Alonso MC, de Jorge EG, 
de Cordoba SR, et al. Complement factor H binds to denatured rather than to 
native pentameric C-reactive protein. J Biol Chem (2008) 283(45):30451–60. 
doi:10.1074/jbc.M803648200 
89. Molins B, Pascual A, Méndez, Llorenç V, Zarranz-Ventura J, Mesquida M, 
et al. C-reactive protein isoforms differentially affect outer blood-retinal bar-
rier integrity and function. Am J Physiol Cell Physiol (2017) 312(3):C244–53. 
doi:10.1152/ajpcell.00057.2016 
90. Molins B, Fuentes-Prior P, Adán A, Antón R, Arostegui JI, Yagüe J, et  al. 
Complement factor H binding of monomeric C-reactive protein downregu-
lates proinflammatory activity and is impaired with at risk polymorphic CFH 
variants. Sci Rep (2016) 6:22889. doi:10.1038/srep22889 
9Molins et al. CRP as a Therapeutic Target in AMD
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 808
91. Chirco KR, Whitmore SS, Wang K, Potempa LA, Halder JA, Stone EM, et al. 
Monomeric C-reactive protein and inflammation in age-related macular 
degeneration. J Pathol (2016) 240(2):173–83. doi:10.1002/path.4766 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Molins, Romero-Vázquez, Fuentes-Prior, Adan and Dick. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) and the copyright owner are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
